Pulse Biosciences Announces Podium Presentation of Nano-Pulse Stimulation™ Technology at Major Aesthetic Procedures Confere...
August 06 2019 - 8:00AM
Business Wire
Pulse Biosciences, Inc. (NASDAQ:PLSE), a bioelectric medicine
technology company bringing to market its proprietary CellFX™
System, today announced its patented Nano-Pulse Stimulation™ (NPS™)
technology will be featured in a series of podium presentations in
the “Hot Topics” session of Controversies and Conversations in
Lasers & Cosmetic Surgery. This prestigious annual scientific
symposium assembles the best and brightest specialists and
innovators in the field of aesthetic procedures and features the
most important advancements in the use of energy-based devices for
dermatology. The event takes place on August 9–11, 2019, in San
Francisco, Calif.
“We are honored that our groundbreaking Nano-Pulse Stimulation
technology which powers our CellFX System was selected for a “Hot
Topics” session during the first day of the upcoming Controversies
meeting of specialists in new technologies,” said Darrin Uecker,
President and CEO of Pulse Biosciences. “It is an acknowledgment to
the clinical investigators and scientific advisors whose ongoing
contributions continue to advance our CellFX System for use in
dermatology.”
The non-thermal mechanism of action harnessed by the CellFX
System is being investigated for a broad range of dermatologic
applications. Pulse Biosciences looks forward to the presentation
of its recent data during this important international forum, which
adds to the expanding professional acceptance of our CellFX System
with its innovative NPS technology and differentiated mechanism of
action.
Session Presentations
“Hot Topics: Nano-Pulse Stimulation Technology” (Friday, August
9, 11:30 am Pacific Time). Presenters:
- Dr. Thomas Rohrer, Mohs skin cancer and dermatologic
surgeon in private practice at SkinCare Physicians in Boston, MA
and Clinical Associate Professor of Dermatology at Brown University
School of Medicine in Providence, RI. Dr. Rohrer will provide an
overview of the many applications of NPS technology and will
feature his own experience in its use treating Seborrheic
Keratosis.
- Dr. Girish Munavalli, Assistant Clinical Professor of
Dermatology at Wake Forest University School of Medicine, Wake
Forest, NC, and founding Medical Director of Dermatology, Laser and
Vein Specialists of the Carolinas, Charlotte, NC. Dr. Munavalli
will present results on the use of NPS technology for the treatment
of Sebaceous Hyperplasia lesions and Warts.
- Dr. Brian Zelickson, Associate Professor at the
University of Minnesota Medical School and founding Medical
Director of Zel Skin and Laser Specialists in Edina, MN. Dr.
Zelickson will discuss early research into the potential for NPS
technology to treat tattoo ink and will provide an update on key
findings from the Basal Cell Carcinoma feasibility study, for which
he was one of five principal investigators.
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that improves and potentially
extends the lives of patients. Our CellFX System is the first
planned commercial product to harness the distinctive advantages of
the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology
to treat a variety of applications for which an optimal solution
remains unfulfilled. NPS technology delivers nano-second pulses of
high amplitude electrical energy to non-thermally clear targeted
cells while sparing adjacent non-cellular tissue. The cell-specific
effects of NPS technology have been validated in a series of
completed and ongoing clinical studies. In addition, early
pre-clinical evidence suggests that NPS technology holds a
promising future in immuno-oncology by demonstrating an ability to
induce immunogenic cell death. We are preparing to commercially
introduce our CellFX System during 2019 as a multi-application
platform designed to address a broad range of dermatologic
conditions. As part of the customer experience, the Company is
offering a utilization-based revenue model and easy-access customer
portal offering a suite of services. Our CellFX procedures offer
customer value across an expanding spectrum of clinical
applications. The initial commercial use will be in the clearance
of common skin lesions, including sebaceous hyperplasia (SH) and
seborrheic keratosis (SK) – two prevalent and difficult-to-treat
benign skin conditions that share high demand among patients and
practitioners for improved and durable aesthetic outcomes that lead
to greater overall satisfaction. For more information about Pulse
Biosciences and our CellFX System, please visit us at
PulseBiosciences.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to or implying Pulse Biosciences’ expectations
regarding commercialization of the CellFX system, regulatory
clearance and the timing of FDA filings or approvals for products
and indications, matters related to its pipeline of product
candidates, future financial performance and business strategies
and other future events. These statements are not historical facts
but rather are based on Pulse Biosciences’ current expectations,
estimates, and projections regarding Pulse Biosciences’ business,
operations and other similar or related factors. You should not
place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions
that are difficult or impossible to predict and, in some cases,
beyond Pulse Biosciences’ control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Pulse
Biosciences’ filings with the Securities and Exchange Commission.
Pulse Biosciences undertakes no obligation to revise or update
information in this release to reflect events or circumstances in
the future, even if new information becomes available.
CAUTION: Pulse Biosciences’ CellFX System and Nano-Pulse
Stimulation (NPS) are for investigational use only.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190806005350/en/
Investors: Brian Dow Sr. Vice President and Chief Financial
Officer IR@pulsebiosciences.com
Gitanjali Jain Ogawa Solebury Trout gogawa@troutgroup.com
646-378-2949
Media: Nadine D. Tosk Nadine Tosk Communications 504-453-8344
nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Sep 2023 to Sep 2024